# Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

> **NCT05435846** · PHASE1 · TERMINATED · sponsor: **Collin Blakely** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer

## Interventions

- **DRUG:** Capmatinib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT05435846
- **Lead sponsor:** Collin Blakely
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-10
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-05-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2024-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435846, "Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05435846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*